Swiss Life Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.2M | Buy |
33,311
+2,023
| +6% | +$387K | 0.03% | 387 |
|
|
2026
Q1 | $5.74M | Buy |
31,288
+6,092
| +24% | +$1.12M | 0.03% | 387 |
|
|
2025
Q4 | $4.43M | Sell |
25,196
-15,249
| -38% | -$2.49M | 0.02% | 435 |
|
|
2025
Q3 | $5.67M | Sell |
40,445
-21,970
| -35% | -$2.97M | 0.03% | 374 |
|
|
2025
Q2 | $7.84M | Buy |
62,415
+3,657
| +6% | +$456K | 0.05% | 278 |
|
|
2025
Q1 | $8.04M | Buy |
58,758
+6,941
| +13% | +$992K | 0.06% | 247 |
|
|
2024
Q4 | $7.92M | Buy |
51,817
+43,227
| +503% | +$7.29M | 0.06% | 232 |
|
|
2024
Q3 | $1.66M | Sell |
8,590
-2,455
| -22% | -$514K | 0.02% | 410 |
|
|
2024
Q2 | $2.56M | Buy |
11,045
+2,914
| +36% | +$633K | 0.03% | 342 |
|
|
2024
Q1 | $1.75M | Sell |
8,131
-18,692
| -70% | -$4.38M | 0.02% | 356 |
|
|
2023
Q4 | $6.95M | Buy |
26,823
+10,531
| +65% | +$2.59M | 0.08% | 267 |
|
|
2023
Q3 | $4.18M | Sell |
16,292
-4,905
| -23% | -$1.31M | 0.06% | 323 |
|
|
2023
Q2 | $6.04M | Sell |
21,197
-18,526
| -47% | -$5.51M | 0.09% | 266 |
|
|
2023
Q1 | $11M | Buy |
39,723
+11,668
| +42% | +$3.23M | 0.17% | 150 |
|
|
2022
Q4 | $7.78M | Sell |
28,055
-5,280
| -16% | -$1.49M | 0.13% | 201 |
|
|
2022
Q3 | $8.9M | Buy |
33,335
+1,011
| +3% | +$215K | 0.15% | 165 |
|
|
2022
Q2 | $6.6M | Buy |
32,324
+24,075
| +292% | +$4.92M | 0.11% | 218 |
|
|
2022
Q1 | $1.73M | Buy |
8,249
+6,718
| +439% | +$1.46M | 0.02% | 432 |
|
|
2021
Q4 | $368K | Sell |
1,531
-14,021
| -90% | -$3.61M | ﹤0.01% | 524 |
|
|
2021
Q3 | $4.4M | Sell |
15,552
-10,960
| -41% | -$3.59M | 0.06% | 310 |
|
|
2021
Q2 | $13.2M | Buy |
26,512
+8,609
| +48% | +$2.61M | 0.13% | 140 |
|
|
2021
Q1 | $5.01M | Sell |
17,903
-3,041
| -15% | -$820K | 0.07% | 304 |
|
|
2020
Q4 | $5.13M | Buy |
20,944
+956
| +5% | +$247K | 0.08% | 287 |
|
|
2020
Q3 | $5.67M | Sell |
19,988
-135
| -0.7% | -$37.7K | 0.08% | 178 |
|
|
2020
Q2 | $5.39M | Buy |
20,123
+13,244
| +193% | +$3.98M | 0.09% | 175 |
|
|
2020
Q1 | $2.18M | Sell |
6,879
-8,473
| -55% | -$2.57M | 0.04% | 285 |
|
|
2019
Q4 | $4.56M | Sell |
15,352
-581
| -4% | -$161K | 0.09% | 190 |
|
|
2019
Q3 | $3.71M | Sell |
15,933
-85,301
| -84% | -$19.9M | 0.05% | 213 |
|
|
2019
Q2 | $23.7M | Buy |
101,234
+28,578
| +39% | +$6.6M | 0.29% | 92 |
|
|
2019
Q1 | $17.2M | Buy |
+72,656
| New | +$22.9M | 0.22% | 100 |
|
|
2018
Q4 | – | Sell |
-3,082
| Closed | -$1.09M | – | 224 |
|
|
2018
Q3 | $1.09M | Sell |
3,082
-551
| -15% | -$190K | 0.01% | 383 |
|
|
2018
Q2 | $1.05M | Sell |
3,633
-9,720
| -73% | -$2.73M | 0.02% | 378 |
|
|
2018
Q1 | $3.66M | Sell |
13,353
-21,114
| -61% | -$6.55M | 0.06% | 218 |
|
|
2017
Q4 | $11M | Buy |
34,467
+11,425
| +50% | +$3.67M | 0.25% | 94 |
|
|
2017
Q3 | $7.21M | Sell |
23,042
-2,253
| -9% | -$667K | 0.19% | 102 |
|
|
2017
Q2 | $6.86M | Sell |
25,295
-1,423
| -5% | -$376K | 0.18% | 104 |
|
|
2017
Q1 | $7.31M | Buy |
26,718
+16,980
| +174% | +$4.8M | 0.2% | 96 |
|
|
2016
Q4 | $2.76M | Sell |
9,738
-4,560
| -32% | -$1.35M | 0.09% | 138 |
|
|
2016
Q3 | $4.48M | Sell |
14,298
-8,444
| -37% | -$2.5M | 0.15% | 101 |
|
|
2016
Q2 | $5.5M | Sell |
22,742
-2,024
| -8% | -$533K | 0.23% | 93 |
|
|
2016
Q1 | $6.45M | Buy |
24,766
+3,028
| +14% | +$800K | 0.27% | 87 |
|
|
2015
Q4 | $6.66M | Buy |
21,738
+2,096
| +11% | +$602K | 0.3% | 85 |
|
|
2015
Q3 | $5.73M | Buy |
19,642
+583
| +3% | +$193K | 0.28% | 89 |
|
|
2015
Q2 | $7.7M | Sell |
19,059
-660
| -3% | -$265K | 0.27% | 77 |
|
|
2015
Q1 | $8.33M | Buy |
+19,719
| New | +$7.77M | 0.34% | 69 |
|
Other funds holding BIIB
Swiss Life Asset Management's BIIB Position: Q2 2026 in Review
Swiss Life Asset Management increased its Biogen (BIIB) stake by 6.5% in Q2 2026, buying an estimated $387K and bringing the position to 33,311 shares worth $7.2M. The position accounts for 0.03% of the portfolio, ranked #387.
Swiss Life Asset Management first reported a position in BIIB in Q1 2015 and has held it in 45 quarters since. The position peaked at $23.7M in Q2 2019. 746 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Swiss Life Asset Management held 33,311 shares of Biogen worth $7.2M as of Q2 2026.
- Swiss Life Asset Management bought 2,023 Biogen shares in Q2 2026, an estimated $387K.
- Biogen made up 0.03% of Swiss Life Asset Management's portfolio in Q2 2026, its #387 holding.
- Swiss Life Asset Management first reported a position in Biogen in Q1 2015 and has held it in 45 quarters since.
- Swiss Life Asset Management's Biogen position peaked at $23.7M in Q2 2019.
- 746 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.